• Target：
• AKAP 250

• Gene Name：
• AKAP12

• Protein Name：
• A-kinase anchor protein 12

• Human Gene Id：
• 9590

• Human Swiss Prot No：
• Q02952

• Mouse Swiss Prot No：
• Q9WTQ5

• Immunogen：
• The antiserum was produced against synthesized peptide derived from human AKAP12. AA range:301-350

• Specificity：
• AKAP 250 Polyclonal Antibody detects endogenous levels of AKAP 250 protein.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• IHC 1:100 - 1:300. IF 1:200 - 1:1000. ELISA: 1:20000. Not yet tested in other applications.

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• AKAP12;AKAP250;A-kinase anchor protein 12;AKAP-12;A-kinase anchor protein 250 kDa;AKAP 250;Gravin;Myasthenia gravis autoantigen

• Molecular Weight(Da)：
• 191kD

• Background：
• The A-kinase anchor proteins (AKAPs) are a group of structurally diverse proteins, which have the common function of binding to the regulatory subunit of protein kinase A (PKA) and confining the holoenzyme to discrete locations within the cell. This gene encodes a member of the AKAP family. The encoded protein is expressed in endothelial cells, cultured fibroblasts, and osteosarcoma cells. It associates with protein kinases A and C and phosphatase, and serves as a scaffold protein in signal transduction. This protein and RII PKA colocalize at the cell periphery. This protein is a cell growth-related protein. Antibodies to this protein can be produced by patients with myasthenia gravis. Alternative splicing of this gene results in two transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008],

• Function：
• caution:The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data.,disease:Antibodies to the C-terminal of gravin can be produced by patients with myasthenia gravis (MG).,domain:Polybasic regions located between residues 266 and 557 are involved in binding PKC.,function:Anchoring protein that mediates the subcellular compartmentation of protein kinase A (PKA) and protein kinase C (PKC).,induction:Activated by lysophosphatidylcholine (lysoPC).,PTM:Phosphorylated upon DNA damage, probably by ATM or ATR.,similarity:Contains 3 AKAP domains.,subcellular location:May be part of the cortical cytoskeleton.,subunit:Binds to dimeric RII-alpha regulatory subunit of PKC.,tissue specificity:Expressed in endothelial cells, cultured fibroblasts and osteosarcoma, but not in platelets, leukocytes, monocytic cell lines or peripherical blood

• Subcellular Location：
• Cytoplasm, cell cortex . Cytoplasm, cytoskeleton . Membrane ; Lipid-anchor . May be part of the cortical cytoskeleton.

• Expression：
• Expressed in endothelial cells, cultured fibroblasts and osteosarcoma, but not in platelets, leukocytes, monocytic cell lines or peripherical blood cells.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs